No connection

Search Results

NUVB

NEUTRAL
$4.45 Live
Nuvation Bio Inc. · NYSE
Target $12.33 (+177.2%)
$1.57 52W Range $9.75
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated May 01, 2026
Market cap
$1.55B
P/E
N/A
ROE
-53.2%
Profit margin
N/A
Debt/Equity
0.22
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
80%
NUVB presents a classic high-risk, high-reward biotechnology profile, characterized by a stable Piotroski F-Score of 4/9 and a very strong liquidity position (Current Ratio 6.95). While revenue growth is explosive at 633.10% YoY, the company remains deeply unprofitable with an operating margin of -81.30% and an extreme forward P/E of 445.00. A significant divergence exists between the 'Strong Buy' analyst consensus (Target $12.33) and the bearish insider sentiment, with $7.05M in officer sales and zero buys. The stock is currently speculative, trading on pipeline potential rather than fundamental value.

Key Strengths

Exceptional revenue growth (633.10% YoY)
Strong liquidity with a Current Ratio of 6.95
Low leverage with a Debt/Equity ratio of 0.22
High Gross Margin (85.22%) indicating strong product pricing power
Strong analyst backing with a 'Strong Buy' consensus

Key Risks

Extreme valuation metrics (P/S of 24.60 and Forward P/E of 445.00)
Heavy insider selling ($7.05M) with no offsetting insider buys
Negative ROE (-53.18%) and ROA (-23.46%)
Bearish technical trend (0/100 score)
High cash burn typical of pre-profit biotech firms
AI Fair Value Estimate
Based on comprehensive analysis
$6.5
+46.1% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
43
Moderate
Value
15
Future
85
Past
50
Health
65
Dividend
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth in revenue, Strong balance sheet liquidity, Severe valuation premium, Negative insider sentiment
Confidence
85%
Value
15/100

Trades at a massive premium; Graham Number is N/A due to lack of earnings.

Positives
No standout positives identified.
Watchpoints
  • Forward P/E of 445.00
  • Price/Sales of 24.60
  • Price/Book of 5.05
Future
85/100

Growth rates are industry-leading, but sustainability is unproven.

Positives
  • 633% Revenue growth
  • Strong analyst price targets ($12.33)
Watchpoints
  • Unproven path to profitability
Past
50/100

Recent recovery offset by long-term value destruction.

Positives
  • 1Y return of +97.8%
Watchpoints
  • 5Y return of -59.1%
  • Consistent earnings misses in recent quarters
Health
65/100

Balance sheet is healthy enough to fund operations, though cash burn continues.

Positives
  • Current Ratio 6.95
  • Debt/Equity 0.22
  • Piotroski F-Score 4/9 (Stable)
Watchpoints
  • Negative operating margins
Dividend
0/100

Typical for growth-stage biotech.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$4.45
Analyst Target
$12.33
Upside/Downside
+177.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NUVB and closest competitors.

Updated 2026-04-30
NUV
Nuvation Bio Inc.
Primary
5Y
-59.1%
3Y
+176.4%
1Y
+97.8%
6M
-13.6%
1M
+3.7%
1W
-11.7%
NBT
Nanobiotix S.A.
Peer
5Y
+91.8%
3Y
+705.8%
1Y
+855.9%
6M
+12.8%
1M
-6.4%
1W
+5.6%
UFP
UFP Technologies, Inc.
Peer
5Y
+289.1%
3Y
+40.8%
1Y
-5.7%
6M
-1.3%
1M
+5.3%
1W
+1.4%
IOV
Iovance Biotherapeutics, Inc.
Peer
5Y
-87.4%
3Y
-32.7%
1Y
+20.9%
6M
+76.2%
1M
-23.6%
1W
+7.9%
IMC
Immunocore Holdings plc
Peer
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
445.0
PEG Ratio
N/A
P/B Ratio
5.05
P/S Ratio
24.6
EV/Revenue
17.24
EV/EBITDA
-5.13
Market Cap
$1.55B

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -81.3%
Gross Margin 85.22%
ROE -53.18%
ROA -23.46%

Growth

Revenue and earnings growth rates

Revenue Growth +633.1%
Earnings Growth N/A
Q/Q Revenue Growth +633.06%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.22
Low debt
Current Ratio
6.95
Strong
Quick Ratio
6.67
Excellent
Cash/Share
$1.52

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
96.9%
Op. Margin
-81.3%
Net Margin
-87.4%
Total Assets
$0.6B
Liabilities
$0.3B
Equity
$0.3B
Debt/Equity
0.95x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-04
$N/A
2026-03-02
$-0.09
-91.1% surprise
2025-11-03
$-0.14
+7.0% surprise
2025-08-07
$-0.14
+1.5% surprise

Healthcare Sector Comparison

Comparing NUVB against 582 companies in the Healthcare sector (37 bullish, 181 neutral, 364 bearish)
Return on Equity (ROE)
-53.18%
This Stock
vs
-87.12%
Sector Avg
-39.0% (Below Avg)
Debt to Equity
0.22
This Stock
vs
2.6
Sector Avg
-91.6% (Less Debt)
Revenue Growth
633.1%
This Stock
vs
120.93%
Sector Avg
+423.5% (Fast Growth)
Current Ratio
6.95
This Stock
vs
4.39
Sector Avg
+58.2% (Stronger)

Similar Companies

Peer comparison within the same industry

NUVB Nuvation Bio Inc.
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-53.2%
Price
$4.45
NBTX Nanobiotix S.A.
BEARISH
Mkt Cap
$1.5B
P/E
-
ROE
-%
Price
$31.83
 Compare with NUVB
UFPT UFP Technologies, Inc.
NEUTRAL
Mkt Cap
$1.5B
P/E
22.7
ROE
17.8%
Price
$198.68
 Compare with NUVB
IOVA Iovance...
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-55.5%
Price
$3.7
 Compare with NUVB
IMCR Immunocore Holdings plc
BEARISH
Mkt Cap
$1.6B
P/E
-
ROE
-9.6%
Price
$31.05
 Compare with NUVB

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

WENTWORTH KERRY A
Officer
Sell
2026-04-17
36,750 shares · $184,279
WENTWORTH KERRY A
Officer
Option Exercise
2026-04-17
36,750 shares · $107,678
LIU DONGFANG
Officer
Sell
2026-04-17
50,000 shares · $251,000
LIU DONGFANG
Officer
Option Exercise
2026-04-17
50,000 shares · $97,000
WENTWORTH KERRY A
Officer
Sell
2026-04-06
200,000 shares · $903,560
WENTWORTH KERRY A
Officer
Option Exercise
2026-04-06
200,000 shares · $381,000
MAKUNJE MOSES
Officer
Stock Award
2026-02-27
50,761 shares
LIU DONGFANG
Officer
Sell
2025-12-01
150,000 shares · $1,173,255
LIU DONGFANG
Officer
Option Exercise
2025-12-01
150,000 shares · $439,500
LIU DONGFANG
Officer
Sell
2025-11-26
20,000 shares · $155,000
LIU DONGFANG
Officer
Option Exercise
2025-11-26
20,000 shares · $72,200
HATTERSLEY GARY
Officer
Sell
2025-11-20
369,051 shares · $2,667,132
HATTERSLEY GARY
Officer
Option Exercise
2025-11-20
369,051 shares · $702,149
LIU DONGFANG
Officer
Sell
2025-11-20
20,000 shares · $140,074
LIU DONGFANG
Officer
Option Exercise
2025-11-20
20,000 shares · $37,400
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-10

NUVB filed a definitive proxy statement on April 10, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

10-K
10-K
2026-03-02

NUVB filed its annual 10-K report on March 2, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures, limiting the available analysis of the company's current financial position and operational risks.

8-K
8-K
2026-03-02
8-K
8-K
2026-01-12
8-K
8-K
2025-11-26
8-K
8-K
2025-11-17
10-Q
10-Q
2025-11-03

NUVB submitted its 10-Q filing on November 3, 2025, which includes a dedicated section for risk factors under Item 1A. Specific financial highlights and detailed risk descriptions were not provided in the available excerpts.

8-K
8-K
2025-11-03

Nuvation Bio (NUVB) likely reported its third-quarter financial results for the 2025 fiscal year.

10-Q
10-Q
2025-08-07

NUVB filed its quarterly 10-Q report on August 7, 2025. The filing includes a section detailing risk factors under Item 1A, although specific financial highlights and risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-08-07

Nuvation Bio (NUVB) likely filed this 8-K to announce its second-quarter financial results.

8-K
8-K
2025-06-11
8-K
8-K
2025-05-23
10-Q
10-Q
2025-05-07
8-K
8-K
2025-05-07
DEF 14A
DEF 14A
2025-04-08
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
9 analysts
Wedbush
2026-04-16
reit
Outperform Outperform
Wedbush
2026-04-02
reit
Outperform Outperform
Wedbush
2026-03-27
reit
Outperform Outperform
UBS
2026-03-03
Maintains
Neutral Neutral
RBC Capital
2026-03-03
Maintains
Outperform Outperform
Wedbush
2026-02-10
reit
Outperform Outperform
RBC Capital
2026-01-21
Maintains
Outperform Outperform
HC Wainwright & Co.
2026-01-12
Maintains
Buy Buy
UBS
2026-01-07
init
Neutral
HC Wainwright & Co.
2025-12-11
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning NUVB from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile